Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433377 | 0.83 | CDC25B (0.50) | ALDH1A1HSD17B10KDM4ETSHRMAPT | |
| SCHEMBL1629983 | 0.83 | PARP1 (0.50) | PARP1ALDH1A1HSD17B10KDM4ELCK | |
| SCHEMBL10249696 | 0.82 | PARP1 (0.58) | PARP1ALDH1A1HSD17B10KDM4ELCK | |
| SCHEMBL7109398 | 0.81 | PRKCI (0.56) | ALDH1A1HSD17B10KDM4EMAPTTDP1 | |
| SCHEMBL8412857 | 0.79 | ALDH1A1 (0.49) | PARP1ALDH1A1HSD17B10KDM4ELCK | |
| SCHEMBL1428434 | 0.79 | ALDH1A1 (0.49) | PARP1ALDH1A1HSD17B10KDM4ELCK | |
| SCHEMBL858826 | 0.78 | PARP1 (0.55) | PARP1ALDH1A1HSD17B10KDM4ELCK | |
| SCHEMBL20987786 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KDM4ELCKSMN1; SMN2 | |
| SCHEMBL19996930 | 0.78 | HDAC1 (0.41) | PARP1ALDH1A1HSD17B10KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL2954473 | 0.77 | ALDH1A1 (0.47) | PARP1ALDH1A1HSD17B10KDM4ELCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11628144-B2 | Iniparib formulations and uses thereof | TRIACT THERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | TRIACT THERAPEUTICS, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-3687501-A1 | INIPARIB FORMULATIONS AND USES THEREOF | Triact Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3654958-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | Triact Therapeutics, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20200113852-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | TRIACT THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| WO-2019067991-A1 | INIPARIB FORMULATIONS AND USES THEREOF | TRIACT THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2018237344-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | TRIACT THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | BIPAR SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2008030891-A2 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030883-A2 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-5877185-A | THERAPY FOR CANCER OR RETROVIRUS | OCTAMER, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0698019-B1 | NOVEL AROMATIC NITRO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER INC (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5652367-A | ANTICANCER AGENTS | OCTAMER, INC. | 1997-07-29 | — | — | US | disclosed |
| WO-1996022791-A9 | NOVEL SYNERGISTIC COMPOSITIONS USEFUL AS ANTI-TUMOR OR ANTI-RETROVIRAL AGENTS | — | 1996-10-03 | — | — | WO | disclosed |
| WO-1996022791-A1 | NOVEL SYNERGISTIC COMPOSITIONS USEFUL AS ANTI-TUMOR OR ANTI-RETROVIRAL AGENTS | OCTAMER, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0698019-A1 | NOVEL AROMATIC NITRO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5464871-A | Aromatic amides | OCTAMER, INC. (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1994026730-A2 | NOVEL AROMATIC NITRO AND NITROSO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | INPP5B, INPPL1, PARP3 | PARP1 12/4885ALDH1A1 1362/4885HSD17B10 4227/4885 |
| US-20200113852-A1 | METHODS OF PATIENT SELECTION AND TREATING TRXR- OR PRDX-OVEREXPRESSED CANCERS | PRDX3, PRDX6, PRDX1 | PARP1 1090/4885ALDH1A1 457/4885HSD17B10 982/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | PARP1 92/4885ALDH1A1 3441/4885HSD17B10 1696/4885 |
| US-11628144-B2 | Iniparib formulations and uses thereof | INPP5B, INPPL1, PARP3 | PARP1 12/4885ALDH1A1 1362/4885HSD17B10 4227/4885 |
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | TOP2B, TOP2A, TOP1 | PARP1 1456/4885ALDH1A1 1190/4885HSD17B10 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.